Collectively, these results indicate that inhibition of wt-p53 in human prostate cancer reduces AIP4 levels to activate CXCR4/CXCL12 axis, ultimately leading to tumor cell bone metastasis (Figure 6C). This evidence concerns the gene TP53 and neoplasm.